Rib-X Pharmaceuticals, Inc. Receives Qualified Infectious Disease Product (QIDP) Designation From the FDA for Radezolid
Published: Oct 10, 2012
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated radezolid as a Qualified Infectious Disease Product (QIDP) for oral and intravenous (IV) use for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). This is the second drug candidate in Rib-X’s pipeline to receive QIDP designation. Rib-X announced in September that the FDA designated delafloxacin as a QIDP for ABSSSI and CABP.